|
NI-0801 is a fully human mAb that binds specifically and selectively to the human chemokine IP-10 (also known as CXCL10) and inhibits the interaction of IP-10 with its cognate receptor and glycosaminoglycans, thereby neutralising IP-10 activity. IP-10 was originally identified as an IFN-γ-inducible gene but is now known to be provoked by various pro-inflammatory mediators such as LPS, IL-1, TNF and IL-12. Numerous cell types produce IP-10 in response to acute or chronic inflammation, recruiting destructive T cells and NK cells (via its receptor CXCR3) to tissues involved in the pathogenesis of: skin inflammation, atherosclerosis, multiple sclerosis, pulmonary/liver fibrosis, type 1 diabetes, autoimmune myasthenia gravis, nephritis, acute cardiac allograft rejection and Celiac Disease. The mechanism of action of NI-0801, therefore, is to block recruitment and activation of pathogenic cells within sites of tissue damage, interrupting the cycle of self perpetuating disease.
|
| Print |
|
|
|
|
| © NovImmune 2008 |
